JAMA Oncology:低脂饮食与乳腺癌生存改善有关,10 年内死亡风险降低 22%

2018-05-28 佚名 康健新视野

5 月 24 日,《JAMA Oncology》发布了一条论文消息,最新的临床随机试验证据指出,平时保持低脂饮食习惯,与乳腺癌死亡风险降低显著相关,乳腺癌患者自诊断后 10 年内全因死亡风险降低 22%。

5 月 24 日,《JAMA Oncology》发布了一条论文消息,最新的临床随机试验证据指出,平时保持低脂饮食习惯,与乳腺癌死亡风险降低显着相关,乳腺癌患者自诊断后 10 年内全因死亡风险降低 22%。

这项研究显示了低脂饮食的又一健康益处,”研究的主要作者、美国加州 City of Hope 医院的 Rowan Chlebowski 教授表示。

关于饮食的健康益处,一直都是大家比较关心的话题。而饮食习惯对乳腺健康的影响,实际上也已经成为了医疗保健领域的热门科普话题。

而本次《JAMA Oncology》的报道,给出了高级别的随机对照研究证据提示,低脂饮食结构,可能会对乳腺癌预后有积极的影响。

研究人员基于美国妇女健康倡议项目下的随机对照试验数据,分析了 40 个临床中心累计约 49,000 名绝经后妇女的长期随访结果,表明了低脂饮食可能带来乳腺癌生存获益的结论。核心数据如下:

这群绝经后妇女人群中,约 40% 患者随机进入到了低脂饮食干预组,每日饮食供热中脂肪热量占比由原来的 30% 以上控制到 20% 以下,剩余患者维持原有饮食习惯不变,作为对照组。

饮食干预研究持续 8 年期间,1,764 名妇女被诊断出乳腺癌。这些乳腺癌患者自从初始诊断后的平均随访时间长达 11.5 年。

整体来看, 诊断乳腺癌患者中共 516 例因各种原因死亡,低脂饮食组相比对照组,自诊断乳腺癌后的 10 年全因死亡风险降低 22%(10 年生存率分别为 82% 和 78%,风险比 0.78,P=0.01)。

低脂饮食组更少患者死于乳腺癌,516 例名因任何原因死亡的乳腺癌患者中,低脂饮食组有 68 例死于乳腺癌,而对照组有 120 例死于乳腺癌,相差 1 倍。

低脂饮食的妇女,死于其他原因的概率也更低,特别是更少发生死于心脏病。在研究期间,64 例保持吃油腻饮食的女性死于心脏病, 而只有 27 名低脂饮食的女性死于心脏病。


平日保持低脂饮食,乳腺癌患者自诊断后的全因死亡风险降低 22%(图片来源:JAMA Oncology)

研究者指出,实施低脂饮食干预,可能改善乳腺癌患者的整体预后结局,但应注意,所带来的死亡风险降低,不全是因为低脂饮食对乳腺癌的影响,部分可归因低脂饮食可能改善了乳腺癌之外的其他原因导致的死亡风险。

Chlebowski 教授强调,这项研究传达出的关键信息是,健康人平日里保持低脂饮食,在一生中任何阶段都可能带来巨大的健康益处。

一些乳腺癌专家认为,这些发现,尤其对乳腺癌幸存者,有确实的指导价值。

" 健康饮食带来的生存获益,究竟是因为健康饮食改善了癌症发展,还是改善了患者整体健康所致,这不得而知。”纽约市 Lenox Hill 医院外科肿瘤学主任 Stephanie Bernik 博士说:“但是,不管怎么样,有一点很明确, 无论对于癌症幸存者还是普通人群,健康饮食都有可能延长预期寿命。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1820662, encodeId=42f7182066297, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Dec 14 08:08:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865445, encodeId=aefc186544584, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 06 04:08:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674452, encodeId=4a4116e445215, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Fri Apr 05 17:08:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255768, encodeId=0e4f1255e6888, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390639, encodeId=c5e21390639f6, content=<a href='/topic/show?id=4fb326339ad' target=_blank style='color:#2F92EE;'>#低脂饮食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26339, encryptionId=4fb326339ad, topicName=低脂饮食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319596, encodeId=719a319596ea, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:45:22 CST 2018, time=2018-05-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1820662, encodeId=42f7182066297, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Dec 14 08:08:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865445, encodeId=aefc186544584, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 06 04:08:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674452, encodeId=4a4116e445215, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Fri Apr 05 17:08:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255768, encodeId=0e4f1255e6888, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390639, encodeId=c5e21390639f6, content=<a href='/topic/show?id=4fb326339ad' target=_blank style='color:#2F92EE;'>#低脂饮食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26339, encryptionId=4fb326339ad, topicName=低脂饮食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319596, encodeId=719a319596ea, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:45:22 CST 2018, time=2018-05-29, status=1, ipAttribution=)]
    2018-08-06 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1820662, encodeId=42f7182066297, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Dec 14 08:08:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865445, encodeId=aefc186544584, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 06 04:08:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674452, encodeId=4a4116e445215, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Fri Apr 05 17:08:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255768, encodeId=0e4f1255e6888, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390639, encodeId=c5e21390639f6, content=<a href='/topic/show?id=4fb326339ad' target=_blank style='color:#2F92EE;'>#低脂饮食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26339, encryptionId=4fb326339ad, topicName=低脂饮食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319596, encodeId=719a319596ea, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:45:22 CST 2018, time=2018-05-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1820662, encodeId=42f7182066297, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Dec 14 08:08:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865445, encodeId=aefc186544584, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 06 04:08:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674452, encodeId=4a4116e445215, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Fri Apr 05 17:08:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255768, encodeId=0e4f1255e6888, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390639, encodeId=c5e21390639f6, content=<a href='/topic/show?id=4fb326339ad' target=_blank style='color:#2F92EE;'>#低脂饮食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26339, encryptionId=4fb326339ad, topicName=低脂饮食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319596, encodeId=719a319596ea, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:45:22 CST 2018, time=2018-05-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1820662, encodeId=42f7182066297, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Dec 14 08:08:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865445, encodeId=aefc186544584, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 06 04:08:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674452, encodeId=4a4116e445215, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Fri Apr 05 17:08:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255768, encodeId=0e4f1255e6888, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390639, encodeId=c5e21390639f6, content=<a href='/topic/show?id=4fb326339ad' target=_blank style='color:#2F92EE;'>#低脂饮食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26339, encryptionId=4fb326339ad, topicName=低脂饮食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319596, encodeId=719a319596ea, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:45:22 CST 2018, time=2018-05-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1820662, encodeId=42f7182066297, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Dec 14 08:08:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865445, encodeId=aefc186544584, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 06 04:08:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674452, encodeId=4a4116e445215, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Fri Apr 05 17:08:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255768, encodeId=0e4f1255e6888, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390639, encodeId=c5e21390639f6, content=<a href='/topic/show?id=4fb326339ad' target=_blank style='color:#2F92EE;'>#低脂饮食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26339, encryptionId=4fb326339ad, topicName=低脂饮食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed May 30 06:08:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319596, encodeId=719a319596ea, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:45:22 CST 2018, time=2018-05-29, status=1, ipAttribution=)]
    2018-05-29 kafei

    了解一下谢谢

    0

相关资讯

Lancet oncol:瑞博悉尼联合内分泌疗法治疗绝经后的HR阳性的、HER2阴性的晚期乳腺癌患者可获得良好疗效

在MONALEESA-2试验中,ribociclib(瑞博悉尼)联合letrozole(来曲唑),相比单用来曲唑,作为绝经后的激素受体(HR)阳性、HER2阴性、晚期乳腺癌患者的一线疗法,可延长患者的无进展存活期。MONALEESA-7试验,对瑞博悉尼联合内分泌疗法用于绝经后的HR阳性的晚期乳腺癌患者的疗效和安全性进行评估。MONALEESA-7试验,是在30个国家的188个城市开展的3期随机化、

NCCN临床实践指南:乳腺癌筛查和诊断(2018.V2)

2018年5月,美国国家综合癌症网络(NCCN)发布了乳腺癌筛查和诊断指南2018年第2版,指南主要内容涉及: 指南更新摘要 病史和体格检查 一般风险筛查/随访 风险增加筛查/随访 症状,阳性检查结果 乳腺疼痛

Lancet oncol:Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者,毒副作用可接受,且具有抗肿瘤效果

Tucatinib是一种有效的选择性口服HER2酪氨酸激酶抑制剂,有潜能为应用当前治疗方案仍病程进展的患者提供耐受良好的新的治疗方案。现有研究人员在美国开展一非随机化、开放性1b期临床试验,探究tucatinib联合卡培他滨或曲妥珠单抗应用于HER2阳性的乳腺癌患者时的推荐2期试验剂量、安全性、药代动力学和预活性。本研究招募年满18岁的HER2阳性的已应用过曲妥珠单抗、帕托珠单抗和曲妥单抗emta

Radiology:术前乳腺MR成像对浸润性小叶癌患者的手术结果影响

本研究旨在通过使用倾向评分匹配来探索术前乳房磁共振(MR)成像与浸润性小叶癌(ILC)患者的手术结果之间相关性,以确定MR检查是否对乳腺癌ILC亚型有用。

Nat Commun:抑制休眠肿瘤细胞的自噬或可阻止乳腺癌复发

根据本周《自然-通讯》发表的一项研究Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence,乳腺癌细胞转移至其它器官并保持休眠状态后,通过自噬确保自身可以长期存活。

全球转移性乳腺癌10年报告:进步与需求

在欧洲肿瘤学院和辉瑞肿瘤学院的共同努力下,包括葡萄牙、美国、澳大利亚、意大利、日本、阿根廷、英国等多个国家的肿瘤专家参与,由葡萄牙的Cardoso教授执笔,近期在Breast杂志发表了2005年至2015年的10年调查报告,阐述了世界范围内转移性乳腺癌的现状,以及不同地区间治疗、可用资源与支持力度的差异,强调了可转移性乳腺癌的治疗进步及尚未满足的临床需求。研究方法这项研究自2015年至2016年